文献速递甲状腺疾病骨质疏松与钙磷/甲状旁腺

促甲状腺激素、甲状腺功能亢进与骨量

Thyrotropin, Hyperthyroidism, and Bone Mass.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

综述探讨促甲状腺激素(TSH)在骨骼重塑中的独立作用。人群观察显示甲状腺功能正常或亚临床甲亢者骨量与正常低值TSH呈负相关;重组人TSH干预试验、基因及病例证据支持该关联。小鼠模型证实TSH的抗破骨效应由肿瘤坏死因子α介导,TSHβ剪接变体提示局部骨骼作用。

要点

  • 甲状腺功能正常或亚临床甲亢者,正常低值TSH与骨量呈负相关。
  • TSH通过抑制破骨细胞生成发挥抗骨吸收作用,并可能影响成骨细胞。
  • 小剂量间歇性重组人TSH显示促合成效应,提示作用呈剂量和频率依赖。

核心结论

  • TSH对骨骼重塑具有独立于甲状腺激素的作用,低TSH与骨量下降相关。
  • TSH的抗破骨效应部分由肿瘤坏死因子α介导,并可能受剂量和频率影响。

研究设计与样本

  • 综述汇总人群观察、小样本干预试验、基因与病例证据及小鼠模型研究。
  • 干预试验使用重组人TSH注射,小鼠模型包括Tshr单倍不足(Tshr+/-)及Tshr缺陷模型。

主要发现

  • 甲状腺功能正常或亚临床甲亢人群中,骨量与正常低值TSH呈负相关。
  • Tshr+/-小鼠甲状腺激素水平正常但出现骨质疏松表型。
  • Tshr缺陷小鼠破骨细胞生成增加由肿瘤坏死因子α介导。
  • 骨髓来源原代成骨细胞培养中低TSH减少成骨细胞生成。
  • 小剂量间歇性重组人TSH在体内显示促合成效应。

临床怎么用

  • 评估骨健康时需关注正常低值TSH及亚临床甲亢状态。
  • 重组人TSH的骨骼效应呈剂量和频率依赖,临床转化需进一步验证。

局限性

  • 干预试验样本量小,证据多来自观察性研究和动物模型。
  • TSHβv局部作用及TSHR与IGF1R、VEGF、Wnt通路交互机制尚未完全阐明。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Thyrotropin (TSH), traditionally seen as a pituitary hormone that regulates thyroid glands, has additional roles in physiology including skeletal remodeling. Population-based observations in people with euthyroidism or subclinical hyperthyroidism indicated a negative association between bone mass and low-normal TSH. The findings of correlative studies were supported by small intervention trials using recombinant human TSH (rhTSH) injection, and genetic and case-based evidence. Genetically modified mouse models, which disrupt the reciprocal relationship between TSH and thyroid hormone, have allowed us to examine an independent role of TSH. Since the first description of osteoporotic phenotype in haploinsufficient Tshr +/- mice with normal thyroid hormone levels, the antiosteoclastic effect of TSH has been documented in both in vitro and in vivo studies. Further studies showed that increased osteoclastogenesis in Tshr-deficient mice was mediated by tumor necrosis factor α. Low TSH not only increased osteoclastogenesis, but also decreased osteoblastogenesis in bone marrow-derived primary osteoblast cultures. However, later in vivo studies using small and intermittent doses of rhTSH showed a proanabolic effect, which suggests that its action might be dose and frequency dependent. TSHR was shown to interact with insulin-like growth factor 1 receptor, and vascular endothelial growth factor and Wnt pathway might play a role in TSH's effect on osteoblasts. The expression and direct skeletal effect of a biologically active splice variant of the TSHβ subunit (TSHβv) in bone marrow-derived macrophage and other immune cells suggest a local skeletal effect of TSHR. Further studies of how locally secreted TSHβv and systemic TSHβ interact in skeletal remodeling through the endocrine, immune, and skeletal systems will help us better understand the hyperthyroidism-induced bone disease.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Kim SM, Ryu V, Miyashita S, et al. Thyrotropin, Hyperthyroidism, and Bone Mass. J Clin Endocrinol Metab. 2021. PMID: 34318885. doi:10.1210/clinem/dgab548

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。